lonafarnib has been researched along with navitoclax in 1 studies
| Studies (lonafarnib) | Trials (lonafarnib) | Recent Studies (post-2010) (lonafarnib) | Studies (navitoclax) | Trials (navitoclax) | Recent Studies (post-2010) (navitoclax) |
|---|---|---|---|---|---|
| 224 | 34 | 90 | 429 | 15 | 401 |
| Protein | Taxonomy | lonafarnib (IC50) | navitoclax (IC50) |
|---|---|---|---|
| Bcl-2-like protein 11 | Homo sapiens (human) | 0.0043 | |
| Apoptosis regulator Bcl-2 | Homo sapiens (human) | 0.0091 | |
| Bcl-2-like protein 1 | Homo sapiens (human) | 0.0168 | |
| Aspartyl/asparaginyl beta-hydroxylase | Homo sapiens (human) | 1.0925 | |
| Bcl-2-like protein 2 | Homo sapiens (human) | 0.07 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonovolias, ID; Chatzopoulou, M; Demopoulos, VJ; Nicolaou, I; Tsiftsoglou, AS; Vizirianakis, IS | 1 |
1 review(s) available for lonafarnib and navitoclax
| Article | Year |
|---|---|
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Leukemia; Multipotent Stem Cells; Neoplastic Stem Cells; Pharmacogenetics | 2010 |